|
KR102208505B1
(ko)
|
2012-12-11 |
2021-01-27 |
앨버트 아인슈타인 컬리지 오브 메디신 |
고처리량 수용체:리간드 확인을 위한 방법
|
|
ES2763198T3
(es)
*
|
2014-07-21 |
2020-05-27 |
Delinia Inc |
Moléculas que selectivamente activan las células T reguladoras para el tratamiento de enfermedades autoinmunes
|
|
KR20170035910A
(ko)
|
2014-08-11 |
2017-03-31 |
데리니아, 인크. |
자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 변형된 il-2 변이체
|
|
CR20170510A
(es)
|
2015-04-10 |
2018-02-26 |
Amgen Inc |
Muteínas de interuquina 2 para la expansión de células t regulatorias
|
|
US20170204154A1
(en)
*
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
NZ775714A
(en)
*
|
2016-05-04 |
2024-12-20 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
JP7071288B2
(ja)
|
2016-05-18 |
2022-05-18 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
US11339201B2
(en)
|
2016-05-18 |
2022-05-24 |
Albert Einstein College Of Medicine |
Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
|
|
CN110167957A
(zh)
*
|
2016-11-08 |
2019-08-23 |
德里尼亚公司 |
用于治疗自身免疫疾病的il-2变体
|
|
CN110177564A
(zh)
*
|
2016-12-13 |
2019-08-27 |
德里尼亚公司 |
多价的调节t细胞调节剂
|
|
US20190352363A1
(en)
|
2016-12-22 |
2019-11-21 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
EP3565829A4
(en)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
KR20190129077A
(ko)
|
2017-03-15 |
2019-11-19 |
팬디온 테라퓨틱스, 인코포레이티드 |
표적화된 면역관용
|
|
IL309479A
(en)
|
2017-03-15 |
2024-02-01 |
Cue Biopharma Inc |
Methods for modulating an immune response
|
|
JP7001285B2
(ja)
*
|
2017-03-29 |
2022-01-19 |
国立大学法人 宮崎大学 |
長時間作用型アドレノメデュリン誘導体
|
|
CA3064435A1
(en)
|
2017-05-24 |
2018-11-29 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
PH12020550661A1
(en)
|
2017-11-21 |
2021-04-19 |
Univ Leland Stanford Junior |
Partial agonists of interleukin-2
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
BR112020011343A2
(pt)
*
|
2017-12-06 |
2020-11-17 |
Pandion Therapeutics, Inc. |
muteínas de il-2 e seus usos
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
|
WO2019131964A1
(ja)
|
2017-12-27 |
2019-07-04 |
協和発酵キリン株式会社 |
Ｉｌ－２改変体
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2019144309A1
(en)
*
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine Fusion Proteins
|
|
WO2019147837A2
(en)
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine fusion proteins
|
|
EP3752178A1
(en)
|
2018-02-16 |
2020-12-23 |
Iltoo Pharma |
Use of interleukin 2 for treating sjögren's syndrome
|
|
PE20210313A1
(es)
|
2018-03-28 |
2021-02-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
|
|
EP3552738B1
(en)
*
|
2018-04-12 |
2024-07-31 |
Sandvik Machining Solutions AB |
A method of producing an additive manufactured object
|
|
CN120349426A
(zh)
|
2018-06-22 |
2025-07-22 |
科优基因公司 |
白介素-2变体及其使用方法
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
JP2021530243A
(ja)
|
2018-07-25 |
2021-11-11 |
アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. |
新規ｉｌ−２１プロドラッグおよびそれを使用する方法
|
|
RU2021105821A
(ru)
|
2018-08-06 |
2021-05-27 |
Медикайн, Инк. |
Соединения, связывающие рецептор il-2
|
|
WO2020035482A1
(en)
|
2018-08-13 |
2020-02-20 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
|
BR112021010983A2
(pt)
*
|
2018-12-21 |
2021-08-31 |
Jiangsu Hengrui Medicine Co., Ltd. |
Variante de interleucina-2 humana ou seu derivado
|
|
MX2021008958A
(es)
|
2019-02-01 |
2021-11-04 |
Regeneron Pharma |
Proteínas de unión a antígeno del receptor gamma anti-il2.
|
|
JP7570338B2
(ja)
|
2019-02-15 |
2024-10-21 |
インテグラル・モレキュラー・インコーポレイテッド |
クローディン６抗体及びその使用
|
|
US11254736B2
(en)
|
2019-02-15 |
2022-02-22 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
|
TW202110885A
(zh)
|
2019-05-20 |
2021-03-16 |
美商潘迪恩治療公司 |
靶向ＭＡｄＣＡＭ之免疫耐受性
|
|
KR20220020879A
(ko)
|
2019-06-12 |
2022-02-21 |
에스크진 파마, 아이엔씨. |
새로운 il-15 프로드럭 및 이를 사용하는 방법
|
|
BR112022001415A2
(pt)
|
2019-07-26 |
2022-06-07 |
Visterra Inc |
Agentes interleucina-2 e os usos dos mesmos
|
|
JP7690458B2
(ja)
*
|
2019-08-12 |
2025-06-10 |
アスクジーン・ファーマ・インコーポレイテッド |
優先的にｉｌ－２ｒアルファに結合するｉｌ－２融合タンパク質
|
|
BR112022008744A2
(pt)
|
2019-11-05 |
2022-07-19 |
Medikine Inc |
Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
|
|
KR20220110209A
(ko)
|
2019-11-05 |
2022-08-05 |
메디카인 인코포레이티드 |
이중 il-2r 및 il-7r 결합 화합물
|
|
WO2021116444A1
(en)
|
2019-12-12 |
2021-06-17 |
Iltoo Pharma |
Interleukin 2 chimeric constructs
|
|
US12091440B2
(en)
|
2019-12-20 |
2024-09-17 |
Regeneron Pharmaceuticals, Inc. |
IL2 and peptide-MHC complex fusion proteins and methods of use thereof
|
|
MX2022008771A
(es)
|
2020-01-14 |
2022-10-07 |
Synthekine Inc |
Metodos y composiciones de muteinas de il2 sesgadas.
|
|
MX2022009302A
(es)
|
2020-02-03 |
2022-11-16 |
Medikine Inc |
Compuestos de unión a il-7r¿.
|
|
WO2021158623A1
(en)
|
2020-02-03 |
2021-08-12 |
Medikine, Inc. |
IL-7Rαγc BINDING COMPOUNDS
|
|
WO2021168079A1
(en)
|
2020-02-21 |
2021-08-26 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a cd39 effector
|
|
US11028132B1
(en)
|
2020-04-07 |
2021-06-08 |
Yitzhak Rosen |
Half-life optimized linker composition
|
|
CA3169949A1
(en)
|
2020-05-12 |
2021-11-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
JP2023526282A
(ja)
|
2020-05-13 |
2023-06-21 |
ボナム セラピューティクス，インク． |
タンパク質複合体の組成物及びその使用方法
|
|
KR20230060514A
(ko)
*
|
2020-09-01 |
2023-05-04 |
다케다 야쿠힌 고교 가부시키가이샤 |
인터루킨-2 뮤테인 및 이의 용도
|
|
JP2023541366A
(ja)
|
2020-09-09 |
2023-10-02 |
キュー バイオファーマ， インコーポレイテッド |
１型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
TW202233673A
(zh)
|
2020-10-23 |
2022-09-01 |
美商雅雪生物治療公司 |
含調節免疫細胞功能之ｃｄ８抗原結合分子之融合物
|
|
JP2023548311A
(ja)
|
2020-10-29 |
2023-11-16 |
ブリストル－マイヤーズ スクイブ カンパニー |
疾患の治療のための融合タンパク質
|
|
JP2023549191A
(ja)
|
2020-11-13 |
2023-11-22 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
ヒトインターロイキン２の変異体又はその誘導体を含む医薬組成物及びその用途
|
|
JP2024502708A
(ja)
|
2020-12-04 |
2024-01-23 |
ビステラ， インコーポレイテッド |
インターロイキン－２作用物質を使用する方法
|
|
IL304365B2
(en)
*
|
2021-03-31 |
2025-04-01 |
Hanmi Pharmaceutical Co Ltd |
A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
|
|
BR112023020597A2
(pt)
|
2021-04-09 |
2023-12-12 |
Selecta Biosciences Inc |
Nanocarreadores sintéticos que compreendem um imunossupressante em combinação com agonistas do receptor de il-2 de alta afinidade para aumentar a tolerância imune
|
|
EP4412631A1
(en)
|
2021-10-06 |
2024-08-14 |
Iltoo Pharma |
Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
US20230263906A1
(en)
|
2022-01-10 |
2023-08-24 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
|
|
US20230322884A1
(en)
|
2022-03-09 |
2023-10-12 |
Selecta Biosciences, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
|
|
WO2023183568A1
(en)
|
2022-03-25 |
2023-09-28 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
|
|
US20250222027A1
(en)
|
2022-04-01 |
2025-07-10 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
US11999771B2
(en)
|
2022-04-07 |
2024-06-04 |
Medikine, Inc. |
IL-7Rαγc ligand immunoglobulin fusion proteins
|
|
WO2023196566A1
(en)
|
2022-04-08 |
2023-10-12 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
|
|
AU2022477937A1
(en)
|
2022-09-12 |
2025-04-10 |
Assistance Publique - Hôpitaux De Paris |
Interleukin-2 for use in treating autism spectrum disorder
|
|
US12049502B2
(en)
|
2022-11-30 |
2024-07-30 |
Integral Molecular, Inc. |
Antibodies directed to claudin 6, including bispecific formats thereof
|
|
EP4648792A2
(en)
|
2023-01-09 |
2025-11-19 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2024229370A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Compositions and methods for treating gvhd
|
|
WO2024229350A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
|
|
WO2024229380A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
|
|
WO2024229432A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2026006809A1
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Multispecific molecules binding tnfr2 and cd25 and uses thereof
|